Antengene
Help people with cancer
live longer and better.
About us

About Us

Historical Development

December 2014

We began engaged in ...
December 2014
We began engaged in drug discovery and development business through 3DMed Beijing, one of our principal operating subsidiaries.

We began engaged in drug discovery and development business through 3DMed Beijing, one of our principal operating subsidiaries.

2014

2016

- In February 2016, ...
2016

- In February 2016, we entered into an agreement with the Alphamab Group in relation to, among others, co-development and exclusive commercialization rights of envafolimab (KN035) in oncological indications.

 

- In December 2016,  we received IND approval from NMPA for envafolimab in December.

2016

2017

- In February 2017, ...
2017

- In February 2017, we launched the first-in-human Phase I trial of envafolimab in the U.S.

 

- In March 2017, we launched Phase I trial of envafolimab in China.

 

- In October 2017, we launched Phase I trial of envafolimab in Japan.

 

- In November 2017, we made a global PCT patent application for 3D011.

2017

2018

- In April 2018, we ...
2018

- In April 2018, we launched a randomized Phase III trial in advanced biliary tract cancer (BTC) in the PRC for envafolimab.

 

- In August 2018, we launched a pivotal Phase II trial of envafolimab in previously treated advanced MSI-H/dMMR cancers.

 

- In September 2018, we obtained global rights to develop, manufacture, import, use, register, commercialize, and grant sub-license for our development of 3D185 from the Haihe Biopharma Group for treatment of tumor and pulmonary fibrosis globally.

 

- In December 2018, we launched the first-in-human Phase I trial of 3D185.

2018

2019

- In September 2019,...
2019
We initiated registered clinical trials of KN035 in North America.

- In September 2019, we received IND approval from FDA for 3D185.

 

- In October 2019, 3DMed Beijing received the High-tech Enterprise Certificate(高新技術企業證書).

 

- In December 2019, we entered into a collaboration and clinical trial agreement with the Alphamab Group and TRACON for clinical development and commercialization of envafolimab for the treatment of sarcoma in the U.S., Canada, Mexico and each of their dependent territories.

2019

January 2020

We received orphan d...
January 2020
In January, 2020, KN035 was awarded Orphan Drug Designation by FDA.

We received orphan drug designation from FDA for envafolimab for the treatment of advanced BTC.

2020

March 2020

We entered into a tr...
March 2020

We entered into a tripartite collaboration agreement with the Alphamab Group and the Simcere Group for the manufacturing, promotion and distribution of envafolimab in the PRC.

2020

October 2020

We licensed-in the d...
October 2020

We licensed-in the development, manufacturing and commercialization rights of 3D1001 and 3D1002 in the PRC from the Haihe Biopharma Group.

2020

November 2020

We entered into a co...
November 2020

We entered into a collaboration and license agreement with Aravive Inc. for an exclusive license to develop and commercialize products that contain 3D229 as the sole drug substance, for the diagnosis, treatment or prevention of human oncological diseases, in mainland China, Taiwan region, Hong Kong and Macau.

2020

December 2020

- We obtained the BL...
December 2020

- We obtained the BLA acceptance from NMPA for envafolimab in the treatment of advanced solid tumors with MSI-H/dMMR.

 

- We entered into a license agreement with SELLAS Life Sciences Group, Inc., a company listed on Nasdaq, and its subsidiary (collectively “SELLAS”) for license of certain intellectual property owned or controlled by SELLAS for the purpose of developing, manufacturing and commercializing our 3D189 and 3D059 for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan region.

 

- We entered into a license agreement with Y-Biologics with respect to license of 3D057 (also known as YBL-013), a T cell bi-specific engager, pursuant to which we will obtain the exclusive right to develop, manufacture and commercialize 3D057 in therapeutic, palliative, prophylactic and diagnostic applications for all therapeutic areas based on Y-Biologics’ Antibody Like Cell Engager (ALiCE) platform technology in China, Hong Kong, Macau and Taiwan region.

2020

January 2021

- We received IND ap...
January 2021

- We received IND approval for 3D011 from NMPA.

 

- Our envafolimab was publicly announced to be accepted for priority review by NMPA.

2021

March 2021

- We filed the IND f...
March 2021

- We filed the IND for 3D229 in China.

 

- We entered into a license agreement with ImmuneOncia Therapeutics, Inc. for an exclusive license for the development, manufacturing and commercialization of 3D197 (also known as IMC-002) in mainland China, Hong Kong, Macau and Taiwan region in respect of oncology indications.

2021

April 2021

We filed the IND for...
April 2021

We filed the IND for 3D229 for a Phase III clinical trial in patients with PROC in China to participate in the MRCT.

2021

May 2021

- We received approv...
May 2021

- We received approval from NMPA to initiate clinical trial for 3D229.

 

- The first-in-human study of envafolimab was published on the Oncologist.

2021

June 2021

The Phase II pivotal...
June 2021

The Phase II pivotal clinical trial result of our envafolimab was published on the Journal of Hematology & Oncology.

2021
December 2014
2016
2017
2018
2019
January 2020
March 2020
October 2020
November 2020
December 2020
January 2021
March 2021
April 2021
May 2021
June 2021
We began engaged in drug discovery and development business through 3DMed Beijing, one of our principal operating subsidiaries.
We initiated registered clinical trials of KN035 in North America.
In January, 2020, KN035 was awarded Orphan Drug Designation by FDA.